Stephen Nicholls: The Search for Effective Lp(a) Therapies Continues
Stephen Nicholls, Program Director of MonashHeart, Intensive Care and Victorian Heart Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in NEJM, adding:
“While it was disappointing that lowering Lp(a) with pelacarsen didn’t result in clinical benefit for patients, it was an important question to ask and a privilege to be involved.
Our patients with high Lp(a) levels need effective therapies. There are ongoing trials that will ask the question in different ways.
The search continues”
Title: Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)
Authors: Leslie Cho, Stephen J. Nicholls, Seth Frndak, Kathy Wolski, Børge G. Nordestgaard, Brian Manning, Eran Leitersdorf, Ulf Landmesser, Venu Menon, Jackie McCluskey, Michael J. Blaha, Ryuichi Morishita, A. Michael Lincoff, Ziqiang Zhao, Jing Wang, Raul D. Santos, Ioanna Gouni-Berthold, Sotirios Tsimikas, Anastasia Lesogor, Hui Cao, Steven E. Nissen
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 11:48Chokri Ben Lamine: Redefining Toxicity Assessment After Immune Effector Cell Therapy
-
Nov 9, 2026, 11:34Shahram Kordasti: Exploring the Pathophysiology of Aplastic Anaemia at ESHBMFS 2026
-
Nov 9, 2026, 11:30When Kidney Function Affects Blood Production – World Anemia Awareness
-
Nov 9, 2026, 10:32Natalie Arnold: The Lp(a) Puzzle – Why Lower Levels May Not Tell the Whole Story
-
Nov 9, 2026, 10:22ISBT Opens Applications for the I TRY IT Programme 2027
-
Nov 9, 2026, 10:08Ibrahim Mansoor: Rare Tests, Common Diseases – Rethinking Autoimmune Diagnostics
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge